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Abstract 
The ability of high viscosity hydroxypropylmethylcellulose (HPMC) to reduce postprandial glucose concentrations 
was assessed in patients with non-insulin-dependent diabetes (NIDDM) and healthy volunteers. The study design con- 
sisted of a two-way crossover, single-dose administration of 10 g prehydrated high viscosity HPMC, or placebo, with 
a standard carbohydrate-rich meal. In patients with NIDDM, HPMC reduced blood glucose concentrations at the 60-, 
75, 90-, 120- and 150-min sampling intervals, with an average reduction in the maximum postprandial blood glucose 
concentration, C,,, of 24% (P < 0.05). The time at which the maximum concentration was reached, T,,,,,, remained 
unchanged. The area under the blood concentration versus time plot, AUCO_,h, was reduced by an average of 15% 
(P < 0.05). The blood concentration profile of insulin followed that of glucose. Concentrations were significantly lower 
than in the placebo phase only at the 120-min sampling time, while pharmacokinetic parameters (C,,,,,. T,,, and 
AUC,_.,,) were unchanged. These results suggest that alterations in the blood glucose profile are mediated by luminal 
events rather than by changes in hormonal response. In contrast to the NIDDM patients, neither the pharmacokinetic 
parameters nor the blood glucose concentrations at specific sampling times were significantly affected by the co- 
administration of HPMC in healthy volunteers. Overall, the results of this study suggest that HPMC may be a useful 
adjunct in the management of NIDDM. 
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1. Introduction 
Certain water-soluble fibers, such as guar and 
pectin, reduce the postprandial blood glucose re- 
sponse to carbohydrate-rich test meals [l-3] and 
oral glucose loads [4-61. These effects have been 
demonstrated in both healthy and diabetic subjects 
[7]. Comparison of results between viscous and 
non-viscous guar has shown that the ability of 
guar to develop a high viscosity in aqueous solu- 
tion is crucial to its ability to reduce postprandial 
glucose concentrations [5]. Like guar and pectin, 
hydroxypropylmethylcellulose (HPMC) can gene- 
rate high viscosities in aqueous solution. HPMC is 
a semi-synthetic cellulose derivative widely used in 
pharmaceutical products as a tablet excipient and 
thickening agent. Recent studies [8] indicate that 
high viscosity HPMC is capable of improving glu- 
cose tolerance in dogs. Medium viscosity HPMC 
had a lesser effect, while low viscosity HPMC fail- 
ed to significantly improve glucose tolerance. 
These results suggest that HPMC, like guar and 
pectin, modulates blood glucose concentrations 
via an increase in luminal viscosity. 
The object of the current study was to determine 
whether high viscosity HPMC could attenuate the 
postprandial blood glucose response in humans, 
and to compare the response in patients with non- 
insulin-dependent diabetes mellitus (NIDDM) 
with that in healthy volunteers. 
2. Materials and methods 
A clinical study was conducted to assess the ab- 
ility of high viscosity HPMC (Dow Chemical, 
Midland, MI) [9.10], to attenuate postprandial 
elevation of glucose concentrations in two groups 
of subjects. The first group comprised 10 patients 
with NIDDM and the second group consisted of 
10 healthy volunteers with mildly elevated serum 
cholesterol concentrations. This control group was 
chosen because it has been shown recently that 
high viscosity HPMC is effective in reducing 
serum cholesterol concentrations in those with 
mildly elevated cholesterol [ 111. The study was 
conducted on a double-blinded randomised two- 
way crossover basis and consisted of two phases, 
a placebo and a test phase, which were separated 
by at least 1 week. All studies were conducted at 
the General Clinical Research Center (GCRC) of 
the University of Michigan Hospitals, after receiv- 
ing approval from the Institutional Review Board 
for studies involving human subjects and from the 
Food and Drug Administration. Written informed 
consent was obtained from each subject prior to 
participation. In the case of NIDDM patients, 
written approval from each patient’s primary 
physician was also obtained prior to entry into the 
study. 
2.1. Exclusion and inclusion criteria 
Subjects were excluded if there was a history of 
major health problems, gastrointestinal (GI) 
disease, regular use of antacids or other drugs 
which may affect GI function, or use of drugs 
which affect cholesterol concentrations (e.g., 
psyllium). Subjects were required to forego alcohol 
and tobacco for a total of 3 days before and 
throughout each study phase. Each subject under- 
went a general medical examination, including 
phlebotomy to assess electrolyte balance, renal 
and hepatic function, and blood morphology. 
Women of childbearing age were screened by 
blood test for pregnancy. Women on birth control 
pills were counseled to take this medication more 
than 3 h away from the study meal. 
NIDDM patients were required to have been 
diagnosed at least 2 years prior to study entry. 
None had experienced a body weight fluctuation 
of greater than 5% within the past year. None were 
receiving insulin, and all were required to 
withdraw from their usual hypoglycemic medica- 
tion for at least three elimination half-lives (to en- 
sure >90% washout) prior to each study day. 
Patients receiving chlorpropamide were excluded 
because of its long elimination half-life. 
Entry criteria for non-diabetic volunteers in- 
cluded a total cholesterol concentration greater 
than 5.15 mmolil (200 mg%) but less than 8.30 
mmol/l (320 mg%), a fasting triglyceride of less 
than 3.45 mmol/l (300 mg%) and an LDL choles- 
terol concentration greater than 4.15 mmol/l (160 
mg%). Subjects whose body weight was not within 
20% of ideal body weight (as determined by 
Metropolitan Life Insurance Co. actuarial tables, 
1983) were excluded. Gender, age and weight of 
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the subjects were matched in the two groups as 
closely as possible, without exceeding the weight 
limitations for non-diabetic volunteers. A sum- 
mary of subject demographics is presented in 
Table 1. Apart from fasting glucose (P = 0.0002) 
and total cholesterol (P = 0.0035), an unpaired I- 
test showed no difference (at the 0.05 level) be- 
tween NIDDM and healthy subjects in the par- 
ameters listed in Table 1. 
2.2. Study protocol 
For a period of 3 days before each phase, all 
subjects were instructed to maintain their carbo- 
hydrate consumption at approximately 60% of the 
total caloric intake and to complete a diary of the 
type and quantity of food consumed. Subjects 
fasted from food but not water after 20:00 h the 
evening before the study day of each phase. In the 
test phase of the study, 10 g of HPMC was ad- 
ministered in prehydrated form as a diet Jello@ 
formulation, at a concentration of 2% (weight in 
volume) resulting in a volume of 500 ml. The 
placebo formulation consisted of 500 ml of diet 
Jell-O@ in which one tablespoon of apple sauce 
was dispersed to modify the texture, thereby 
reducing the ability of subjects to discern the 
placebo from the test phase. The same amount of 
Table 1 
Demographics and relevant biochemical data for patients with 
NIDDM and healthy volunteers who participated in the study 
NIDDM Non-diabetic 
Number 
(Males/Females) S/5 515 
Age (years) 50 zt 9 (28-59) 41 f 10 (29-59) 
Weight (kg) 97 * 22 (68-138) 87 f 18 (59-113) 
Body mass index 
(kglm’) 31.3 * 5.3 30.2 zt 6.5 
Fasting blood 
glucosea 
(mmolil) 12.2 f 4.21 5.7 zt 0.72 
Fasting insulin 
(pmohl) 286.3 f 380.3 126.3 zt 72.5 
Total cholesterol” 
(mmol/I) 5.10 f 0.85 6.15 f 0.50 
Values are presented as mean f SD. and/or mean (range). 
aParameters which differed significantly (as determined by un- 
paired t-test at the 0.05 level) between NIDDM patients and 
healthy volunteers. 
gelatin (8.5 g) was used in both the test and 
placebo formulations. The diet Jello@ formulations 
were consumed during the course of a breakfast, 
which was served at OS:00 h and consisted of 1 oz 
cereal with 8 oz milk, two pieces of toast with 
margarine and jam, coffee or tea and 6 oz orange 
juice. This breakfast contained a total of 600 kcal 
with 13.7 g protein (9% of calories), 102 g carbohy- 
drates (67% of calories) and 16 g fat (24% of 
calories). Subjects were instructed to consume 
both the breakfast and the diet Jell-O@ formula- 
tion over a period of more than 10 but less than 20 
min. Blood samples were drawn prior to and at 15, 
30,45,60, 75,90, 120, 150, 180,210, 240, and 360 
min following the consumption of both breakfast 
and Jell-O@ with time zero taken as the time at 
which ingestion of both the meal and the diet Jell- 
O” was complete. At 2-h intervals after the con- 
sumption of the breakfast, subjects were asked to 
complete a questionnaire regarding adverse effects 
including heartburn, bloating, gastric discomfort, 
flatulence, GI cramping, diarrhea, headache and 
palpitations and permitted to drink up to 8 oz of 
water. 
Studies in patients with NIDDM were perform- 
ed on an in-patient basis. Patients reported to the 
GCRC the afternoon of the pre-study day, had a 
preselected diabetic dinner and spent the night at 
the GCRC. They were woken up at about 06: 15 h 
to have their catheters inserted. Following the 
completion of the second phase of the study they 
were evaluated for electrolyte balance, renal and 
hepatic function, and blood morphology. Studies 
in non-diabetic volunteers were performed on an 
out-patient basis with the volunteers reporting to 
the GCRC by 07: 15 h on the morning of the study 
days. 
2.3. Assays 
Blood glucose concentrations were measured 
using a Beckman@ glucose analyser 2 (Fullerton, 
CA) which determines glucose by means of the 
oxygen rate method [ 121 employing a Beckman 
Oxygen Electrode. Typical precision in glucose 
measurements on a day-to-day basis is within 0.2 
mmol/l (standard deviation) for values in the nor- 
mal range. For a 8.3-mmol/l aqueous standard, 
glucose measurements deviate less than 0.1 mmol/l 
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within a run. If the sample concentration was less 
than 13.8 mmolil, determination of blood glucose 
was made at least in duplicate, while if the concen- 
tration was higher than 13.8 mmol/l the determina- 
tion was made at least in triplicate. 
A double-antibody radioimmunoassay was used 
for measuring plasma insulin levels [ 131. The inter- 
assay and intra-assay variabilities are 6.2% and 
2.0%, respectively. 
2.4. Analysis of data 
For both glucose and insulin data, the maxi- 
mum concentration, Cmax, and the time at which 
this concentration occurred, T,,,, were obtained 
directly from the individual blood or plasma con- 
centration versus time profiles. The area under the 
concentration versus time profiles for the first 6 h 
following the consumption of the meal, AU&,,, 
was calculated geometrically using the trapezoidal 
rule [14], after excluding the area beneath the fast- 
ing level. Differences in all three pharmacokinetic 
parameters as well as in the concentration at each 
specific sampling time were assessed with repeated 
measures analysis of variance using the program 
SuperANOVA@ (Abacus Concepts, Berkeley, 
CA). The effect of the order in which the subjects 
participated in the two phases of the study, and the 
effect of the subject group (NIDDM vs. non- 
diabetic) on postprandial blood glucose and plas- 
ma insulin concentrations were also evaluated. In 
cases where variance increased with mean param- 
eter value, the analysis was performed on log 
transformed data to remove this bias. The signifi- 
cance of the reported adverse effects was assessed 
with the Wilcoxon’s signed rank test. In all cases 
differences were considered significant at the 0.05 
level. 
3. Results 
Figs. 1 and 2 show the mean postprandial blood 
glucose and insulin concentrations versus time in 
the NIDDM and the non-diabetic groups, respec- 
tively. Asterisks denote statistically significant dif- 
ferences between phases at specific sampling times. 
Tables 2 and 3 summarize the pharmacokinetic an- 
alysis of the glucose and insulin concentrations in 
both the NIDDM patients and in the non-diabetic 
volunteers. 
3.1. Order of phases 
In both groups the order in which subjects par- 
ticipated in the two phases had no effect on either 
blood glucose or plasma insulin levels, indicating 
a lack of carry-over effect. 
3.2. Effect of HPMC in patients with NIDDM 
Blood glucose concentrations were significantly 
lower at the 60-, 75, 90-. 120- and 150-min sam- 
pling times following administration of HPMC 
(Fig. 1A). Compared with the placebo phase, 
c max was an average of 23.6% lower in the test 
phase (Table 2) and AiJCO_6L was reduced by an 
average of 14.8%. T,,, values were not signifi- 
cantly affected by the presence of HPMC. 
Plasma insulin concentrations were little af- 
fected by administration of HPMC. The trend for 
insulin concentrations to be lower in the HPMC 
phase reached significance only at 120 min. Phar- 
macokinetic parameters Cmax, T,,.,,, and AUC’O-~~, 
were not affected (Table 3). 
3.3. Effect of HPMC in non-diabetic subjects 
HPMC had no significant effects on either the 
postprandial blood glucose concentrations (Fig. 
2A) nor the glucose pharmacokinetic parameters 
(Table 2). 
After administration of HPMC, plasma insulin 
concentrations were significantly lower at the 60-, 
75 and 90-min intervals, but were higher 240 min 
after ingestion of the HPMC meal was completed 
(Fig. 2B). However, pharmacokinetic parameters 
( Gax, T’ax, AU&,,) for insulin in the non- 
diabetic group were not affected by HPMC (Table 
3). 
3.4. NIDDM versus non-diabetic subjects 
As expected, the postprandial blood glucose 
concentrations were significantly higher in pa- 
tients with NIDDM than in the non-diabetic 
volunteers throughout the sampling period (O-360 
min). Both C,,,,, 
. . 
and A UC&, were significantly 
higher in the NIDDM than in non-diabetic sub- 
jects with T,,,,, occurring significantly later in the 
NIDDM than in the non-diabetic group (Fig. 1 A 
vs. Fig. 2A). Repeated measures ANOVA showed 
that these differences between NIDDM and non- 
diabetic subjects were significantly greater in the 











Fig. 1. (A) Mean plasma glucose and (B) plasma insulin concentrations in 10 NIDDM subjects after consuming a carbohydrate rich 
breakfast without (0) or with HPMC (0). Asterisks denote significant differences between treatments at a given time interval. 
placebo phase than in the test phase (as determin- 
ed by the Treatment x Group interaction). 
Both insulin C_ and insulin AW&, were 
significantly lower in patients with NIDDM than 
in non-diabetic volunteers. Although there was a 
trend for plasma insulin concentrations in the 
NIDDM patients to be lower than in the non- 
diabetic volunteers, this did not reach significance 
at any specific sampling time. As with the glucose 
concentrations, T,,,,, occurred significantly later 
in the NIDDM than in the non-diabetic group. 
3.5. Adverse effects 
In both the NIDDM and non-diabetic groups, 
subjects occasionally reported GI related adverse 
effects such as gastric discomfort or bloating. The 
effects were mild and not statistically different 
from the placebo phase, 
4. Discussion 
Hydroxypropylmethylcellulose is a semisyn- 
thetic ether of cellulose which, when dispersed in 
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Fig. 2. (A) Mean plasma glucose and (B) plasma insulin concentrations in IO non-diabetic subjects after consuming a carbohydrate 
rich breakfast without (0) or with HPMC (0). Asterisks denote signilicant differences between treatments at a given time interval. 
aqueous solution, results in a striking increase in 
the viscosity of the solution. In this respect it is 
similar to naturally occurring water-soluble fibers 
such as guar and pectin. The viscosity achieved 
depends on the concentration of the polymer and 
its molecular weight. A 2% solution of the HPMC 
combination used in this study yields a viscosity of 
about 30 000 cP at a shear rate of 1 s-r, much 
higher than the viscosity of the contents of the pro- 
ximal small intestine after a meal (about 40 cP) 
and comparable with that formed in solutions con- 
taining 3% guar (unpublished data). Guar and 
pectin significantly reduce postprandial hyper- 
glycemia and hyperinsulinemia to a similar degree, 
in both diabetic and healthy individuals [15]. It is 
therefore of interest to compare the ability of 
HPMC to attenuate postprandial glucose levels 
with published data for guar and pectin. 
4. I. Patients with NIDDM 
Seven studies in diabetic subjects have shown 
that when guar is administered in doses ranging 
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Table 2 
Effect of high viscosity HPMC on the postprandial maximum rise in blood glucose concentration, C,,, (mmohl), the time that this 
occurred, T,,, (min), and the rise of the area under the concentration versus time curve, AU&,, (mmol min/l), in NIDDM patients 
and healthy subjects 
NIDDM 
Placebo Test P 
Non-diabetic 
Placebo Test P 
Gllax 1.24 f 1.59 5.53 f I .42 0.0099 2.99 f 1.80 2.85 zt 1.32 NS 
Gl,, 90 f 37 II2 f 12 NS 25 f 10 21 f IO NS 
A ucO-6h 1318 f 405 II23 f 298 0.0096 212 f I58 222 l 195 NS 
Data are presented as mean f S.D. 
NS indicates that differences are not significant. 
from 7 to 15 g the maximum postprandial glucose 
concentration, C,,,, is reduced by percentages 
ranging from 2% (NS) to 61% [ 151. A similar range 
of results has been observed with pectin. A dose of 
7 g pectin was shown to reduce the maximum 
postprandial glucose concentration by 12X, while 
15 g reduced the maximum postprandial glucose 
concentration by 44% [15]. In the current study, 
10 g of HPMC had an effect lower than that of the 
median response to guar (53”/0) but comparable 
with that of the median response to pectin (33%) 
with a reduction in the peak glucose concentration 
of 24%. 
Guar has been shown to reduce the extent of 
glucose absorption, as measured by the area under 
the curve (AUC), for the first l-2 h after the meal 
[1,5,6,16]. However, when AUC was measured 
over longer intervals, no significant reductions 
Table 3 
Effect of high viscosity HPMC on the postprandial maximum rise in plasma insulin concentration, C,,, (pmol/l). the time that this 
occurred, T,.,,,, (min), and the rise of the area under the concentration versus time curve, AlJC,_,, (pmol min/l). in NIDDM patients 
and healthy subjects 
NIDDM 
Placebo 
481 zt 456 
96 f 42 
77 031 * 70 552 
Test P 
390 f 310 NS 
88 + 72 NS 
64331 f 44758 NS 
Non-diabetic 
Placebo Test P 
1309 f 911 II98 zt 875 NS 
42* I8 30 f 17 NS 
124745 f 85268 109 792 zt 77 661 NS 
were observed. We found that the AUC measured 
over the first 6 h after meal intake was reduced by 
an average of approximately 15% when we ad- 
ministered 10 g HPMC with the meal. These re- 
sults suggest that, unlike guar [17,18], HPMC not 
only delays but also reduces the extent of glucose 
absorption. It is possible that if HPMC were ad- 
ministered in a less hydrated, more palatable for- 
mulation, the effects on glucose would be more 
modest. Even so, high viscosity HPMC appears to 
have two potential advantages versus other adju- 
vant therapies for NIDDM patients. These lie in 
its lack of fermentability, and therefore lesser 
tendency to produce flatulence [ 111, and, more im- 
portantly, its greater ability to control cholesterol 
levels [ll]. 
Insulin concentrations tended to follow the glu- 
cose profile. There was a tendency for insulin con- 
Data are presented as mean f SD. 
NS indicates that differences are not significant. 
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centrations to be lower during the first 3 h after the 
meal, but higher thereafter when HPMC was ad- 
ministered. Differences reached significance only 
at the 120-min sampling time. The similarity in the 
shapes of the blood concentration profiles for glu- 
cose and insulin, with tendency to a reduction in 
C,,, and a delay in T,,,,, suggest that glucose is 
gradually absorbed over a prolonged period. 
These results are consistent with the hypothesis 
that the effect of HPMC on glucose concentrations 
is mediated primarily via induction of a high 
luminal viscosity, with an associated reduction in 
nutrient diffusivity [8,10]. 
The insulin results for HPMC differ from those 
with guar, which has a tendency to decrease 
postprandial C,,, insulin levels of diabetic sub- 
jects, with reductions of 20% (NS) in one study 
and 68”% in another [ 151. Reduced GIP secretion 
has been considered responsible for the smaller 
rise in plasma insulin observed in IDDM patients 
when guar was added to meals [ 191. 
4.2. Non-diabetic volunteers 
In contrast to the response in patients with 
NIDDM, there was no detectable change in serum 
glucose concentrations when HPMC was ad- 
ministered with the carbohydrate-rich meal. As in 
the case of NIDDM patients, literature data for 
guar is somewhat equivocal. In 11 studies in non- 
diabetics, doses between 5 and 15 g of guar 
resulted in reductions in blood glucose ranging 
from 0% (NS) to 68%. with a median of 35% [IS]. 
In five studies with pectin, doses of 10-14.5 g 
resulted in changes ranging from an increase of 4% 
(NS) to a reduction of 55% with a median of 17% 
reduction [15]. Lack of consistency of results 
among studies is probably related to variations in 
the dose of fiber administered, the formulation 
given, timing of administration, carbohydrate con- 
tent and subject demographics. In the current 
study we attempted to standardize timing of 
HPMC versus meal intake by asking subjects to 
alternate ingestion of portions of the meal with 
portions of the HPMC formulation. We also used 
a prehydrated formulation of HPMC to maximize 
reproducibility of the viscosity that was induced 
intraluminally. Another difference from previous- 
ly reported studies is that we selected non-diabetic 
volunteers who had mildly elevated cholesterol 
levels as our control group, whereas other studies 
did not screen specifically for cholesterol. These 
differences in study protocol, along with the struc- 
tural differences between HPMC and guar and 
pectin, may account for the lack of effect of 
HPMC on glucose concentrations observed in our 
control group. We attributed the absence of an 
effect with HPMC in our non-diabetic volunteers 
versus our NIDDM patients to the greater ability 
of insulin to control blood glucose levels in the 
non-diabetics. 
Insulin profiles in the non-diabetic volunteers 
mirrored glucose concentrations as was the case in 
NIDDM patients. Although levels differed be- 
tween phases at four sampling times (lower at 60, 
75 and 90 min and higher at 4 h), there were no 
changes in the pharmacokinetic parameters. This 
borderline effect concurs with literature data for 
guar and pectin. A wide variety of effects ranging 
from no effect to large reductions in postprandial 
insulin concentrations have been observed for 
both guar and pectin [15]. The reduction in the 
postprandial insulin response to the meal that is 
observed for healthy volunteers when guar is 
added to the meal has been attributed to a reduc- 
tion in GIP secretion [19]. 
4.3. Comparison with canine data 
Previous studies in non-diabetic dogs indicated 
that co-administration of HPMC with glucose 
meals resulted in a 62% reduction in C,,,,, and a 
54% reduction in AUC’O_3h for blood glucose [8]. 
The discrepancy between the canine and human 
data might be attributable in part to the faster gas- 
tric emptying and slower small intestinal transit of 
non-diabetic humans compared with non-diabetic 
dogs [20]. The effects of HPMC on postprandial 
hyperglycemia seem attributable, at least in part, 
to reduced absorption of nutrients (impaired radi- 
al diffusion of nutrient molecules to the gut wall 
and delayed gastrointestinal transit [&lo]). 
Therefore, the slower the meal passes through the 
small intestine under normal meal intake condi- 
tions, the less pronounced the effect of HPMC is 
expected to be. A related factor would be that the 
AUC was calculated over a shorter interval in the 
case of the canine data. 
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4.4. Potential use in diabetics with hyperchol- 
esterolemia 
5 
Our results indicate that addition of high viscos- 
ity HPMC to carbohydrate-rich meals results in 
improved control of postprandial hyperglycemia 
in NIDDM subjects, without significantly affec- 
ting insulin levels. A proportion of patients with 
NIDDM also have hypercholesterolemia [21]. In 
previous studies [l 11, we demonstrated that ad- 
ministration of high viscosity HPMC with meals 
for 1 or 2 weeks results in a reduction of total and 
LDL-cholesterol levels in subjects with mildly 
elevated cholesterol levels. A role for HPMC in the 
treatment of NIDDM patients who also have 
hypercholesterolemia, as a means of simultaneous- 
ly lowering cholesterol and contributing to the 
control of postprandial glucose concentrations, 
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